Medical resource use and costs associated with chylomicronemia

Journal of Medical Economics

Volumn 16, Issue 5, 2013, Pages 657-666

  Gaudet, Daniel ^a   Signorovitch, James ^b   Swallow, Elyse ^b   Fan, Liangyi ^b   Tremblay, Karine ^a   Brisson, Diane ^a   Meyers, Charles ^c   Gruenberger, Jean Bernard ^c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b ANALYSIS GROUP   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acute pancreatitis; Chylomicronemia; Cost of illness; Economics; Familial chylomicronemia syndrome

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID DERIVATIVE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPOTHYROIDISM; ICD-9; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; UNITED STATES;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; HYPERLIPOPROTEINEMIA TYPE V; HYPOLIPIDEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PANCREATITIS; PATIENT ACUITY; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 84876348493     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.779277     Document Type: Article

References (33)

1. Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1992;37:249-73
2. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007;357:1009-17
3. Benlian P, De Gennes JL, Foubert L, et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;335:848-54 (Pubitemid 26304066)
4. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res 2011;52:189-206
5. Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009;169:572-8
6. Bathnagar D. Hypertriglyceridemia. In: Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in health and disease. London: Arnold Publishers and Oxford University Press, 1999. p 737-53
7. O'Brien T, Dinneen SF, O'Brien PC, et al. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993;68: 860-6 (Pubitemid 23266121)
8. Brunzell JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. Trans Assoc Am Physicians 1973;86:245-54
9. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994;78:117-41 (Pubitemid 24029410)
10. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th edn. New York, NY: McGraw-Hill, 2001. p 2789-16
11. Tremblay K, Methot J, Brisson D, et al. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol 2011;5:37-44
12. Fung MA, Frohlich JJ. Common problems in the management of hypertriglyceridemia. CMAJ 2002;167:1261-6 (Pubitemid 35373400)
13. Brunzell JD, Bierman EL. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am 1982;66: 455-68 (Pubitemid 12115376)
14. Christian JB, Bourgeois N, Snipes R, et al. Prevalence of severe (500 to 2000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol 2011;107:891-7
15. Brisson D, Methot J, Tremblay K, et al. Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. Pharmacogenet Genomics 2010;20:742-7
16. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998;27:551-67, viii (Pubitemid 28446947)
17. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9 (Pubitemid 34251969)
18. Okosun IS, Chandra KM, Boev A, et al. Abdominal adiposity in U.S. adults: prevalence and trends, 1960-2000. Prev Med 2004;39:197-206 (Pubitemid 38797973)
19. Golden SH, Robinson KA, Saldanha I, et al. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94:1853-78
20. Thomson Reuters MarketScan- Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases. Ann Arbor, MI: Thomson Reuters (Healthcare) Inc.; 2010
21. The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Hyattsville, MD (NCHS) and Baltimore, MD (CMS): The National Center for Health Statistics (NCHS) and the Centers for Medicare and Medicaid Services, 2010
22. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation 1965;31:321-7
23. Rice J. Mathematical statistics and data analysis. 2nd edn. Belmont, CA: Duxbury Press, 1995. p 492-4
24. Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956. p 75-83
25. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet 2008;371: 143-52
26. SAS Institute Inc. SAS- software, Version 9.2 for Microsoft- Windows XP. Copyright-. Cary, NC: SAS Institute Inc., 2008
27. Balu S, Thomas 3rd J, Incremental expenditure of treating hypertension in the United States. Am J Hypertens 2006;19:810-6; discussion 817 (Pubitemid 44107695)
28. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615
29. Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010;11:55-60
30. Frey CF, Zhou H, Harvey DJ, et al. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006;33:336-44 (Pubitemid 44690721)
31. Christian JB, Arondekar B, Buysman EK, et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol 2012;6:450-61
32. Fagenholz PJ, Fernandez-del Castillo C, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas 2007;35:302-7 (Pubitemid 350307371)
33. Gaudet D, Gagne C. La morbidité é conomique des dyslipidé mies familiales au Qué bec. Les actualité s du coeur 1997;2:12